News

Pharma has taken a moderated approach to price hikes to start the year, a new analysis concludes. Credit: Getty/Gti337. It's evidence to justify pharma's current fears. Amid all of the recent scrutiny on drug pricing—and after enjoying years of great pricing freedom in the U.S.—drugmakers have reined in their price hikes since the start of 20...

  Wednesday, February 22, 2017 Activist investor Carl Icahn has moved into Bristol-Myers Squibb, touching off more megamerger speculation. After all, the company has seen a major reversal of fortunes since its immunotherapy Opdivo fell short in a key lung cancer study last fall, and just yesterday, it bowed to another activist by adding th...

Last month, a couple of analysts addressed Bristol-Myers Squibb as a takeover target for some rival pharma giant. The gist? The combination of disappointments on its cancer blockbuster Opdivo plus a solid product line-up could well put a bullseye on the company—and its “very logical, very rational” management team wouldn’t dismiss offers out of ...

Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail. The failure of the BACE inhibitor to move the needle in the trial of 2,000 patients with mild-to-moderate Alzheimer’s dented Merck’s stock price after hours and dealt another blow to the amyloid hypothesis. Executives at Merck pulle...